Drug profile · INN
alectinib
ALECENSA
alectinib (ALECENSA) is a eml4-alk. Associated with Hoffmann-La Roche.
Drug details — alectinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 12
- Data quality
- 0.83
Quick answer
alectinib (ALECENSA) is a eml4-alk. Associated with Hoffmann-La Roche.
Key facts
Mechanism of action
EML4-ALK
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
Roche's Alecensa Secures Expanded Approval in Japan for ALK-Positive Lung Cancer
Roche has secured an expanded approval for Alecensa in Japan, broadening its therapeutic reach for patients with ALK-positive non-small cell lung cancer. This development underscores Roche's commitment to advancing targeted therapies in oncology.
Roche Expands Alecensa Approval in Japan: Implications for Pharma
Roche has received approval to expand Alecensa's use in Japan for all ALK tumor types. This article explores the implications for pharma stakeholders.
Roche's Alecensa Expansion: Implications for Pharma Stakeholders
Roche's Alecensa has received approval for the treatment of all ALK tumor types in Japan, marking a significant regulatory milestone. This article explores the implications for pharma stakeholders.
Treatment Sequencing in NSCLC: Insights from EU Guidelines and ESMO
This article delves into the latest EU guidelines and ESMO recommendations on treatment sequencing for non-small cell lung cancer (NSCLC), highlighting osimertinib's role.
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is alectinib?
alectinib (ALECENSA) is a eml4-alk. Associated with Hoffmann-La Roche.
What is the brand name for alectinib?
ALECENSA is a marketed brand name for alectinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.